ICER’s Latest: Draft Evidence Report on New ALS Treatments

ICER’s Latest: Draft Evidence Report on New ALS Treatments

On June 14, 2022, ICER released its draft evidence report, “AMX0035 and Oral Edaravone for Amyotrophic Lateral Sclerosis.” This is the first step in ICER's review process. A final evidence report is expected to be released in mid-September. Background on ALS...

read more
More of the Same: ICER’s latest salvo on rare diseases

More of the Same: ICER’s latest salvo on rare diseases

Earlier this month, ICER released a white paper titled “The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability.” If you have been monitoring ICER’s work over the years, the paper likely matches your expectations. Ostensibly, the...

read more
Event: Health Plan Heroes Awards Program and Roundtable

Event: Health Plan Heroes Awards Program and Roundtable

Patients Rising's first annual Health Plan Heroes event will honor companies that have adopted innovative benefit design for their employees. In addition, a panel of experts will have a roundtable discussion on ways for employers to enhance patient access to care as...

read more